SLC3A2 and urogenital neoplasm: For the majority of tumors assessed, significantly higher levels of SLC3A2 expression were observed in malignant vs normal tissues, most notably in colorectal, breast, genitourinary cancers and cutaneous melanomas (figure 3A).